Corneal Artificial Endothelial Cell Transplantation:
This study will be led by Professor Francis Ma, MD, director of the Division of Cornea and External Diseases, Scripps Clinic Medical Group. The clinical research will involve at least 10 prominent corneal surgeons across the United States at various surgical centers.
"The start of this clinical study in America is an exciting moment for our field. EndoArt represents a completely innovative approach to the treatment of chronic corneal edema. "I am honored to lead this important research and help evaluate a technology that may change the future of corneal endothelial disease management." – Professor Francis Ma
"Receiving FDA approval for IDE is a significant milestone for EyeYon Medical and patients with corneal endothelial diseases, a market valued at more than $1 billion globally." - Nahum Ferreira, CEO of EyeYon Medical
"EndoArt® has been rapidly gaining traction in Europe, and this study brings us one step closer to providing new hope for patients who are not a viable option for human tissue transplants in the United States."
⸻
Redefining the treatment of corneal edema
EndoArt, EyeYon Medical's pioneering synthetic endothelial implant, has been evaluated in several clinical studies outside the United States and has received the CE mark. In Europe, this technology has been gradually accepted by surgeons and commercial expansion. In China, a dedicated clinical study has been successfully conducted and confirmed the safety and effectiveness of the device in different patient populations.
So far, more than 800 EndoArt implants have been performed worldwide, and follow-up data up to 7 years show long-term corneal clarity, stability, and sustained therapeutic benefit. These achievements solidify EndoArt's position as a transformative treatment option in corneal care at the global level.
⸻
About EyeYon Medical Ltd.
EyeYon Medical Ltd. is an active company in the field of eye medical equipment that develops innovative solutions for corneal diseases. EyeYon Medical is responding to one of the largest unmet needs in ophthalmology – the lack of effective and affordable solutions for corneal blindness, when only one cornea is available for every 70 patients in need.
In the United States, the EndoArt implant is an investigational device restricted to research use and not available for sale.
